Rare disease antibody developer Quellis pulls in $17mm Series A round
Executive Summary
Perceptive Advisors’ Perceptive Xontogeny Venture Fund led a $17mm Series A financing for Quellis Biosciences Inc. (next-generation antibodies for rare diseases).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice